[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369669-105":59,"doc-detail-369669-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","investigating-risk-of-cancer-with-sodium-glucose-cotransporter-2-inhibitors-a-disproportionality-analysis-in-the-who-global-pharmacovigilance-database-vigibase","Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors - A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase®","","Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) have expanded rapidly because of cardiovascular benefits, yet their association with cancer risk remains uncertain due to limitations in prior studies. Using a hypothesis-generating disproportionality approach, an analysis of Vigibase® reports from 2014–2023 compared SGLT-2i use with GLP-1 analogues and DPP-4 inhibitors to evaluate reporting signals across cancer subtypes. Results showed increased reporting for bladder and kidney cancers, while other subtypes were not similarly elevated.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/investigating-risk-of-cancer-with-sodium-glucose-cotransporter-2-inhibitors-a-disproportionality-analysis-in-the-who-global-pharmacovigilance-database-vigibase/369669/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/investigating-risk-of-cancer-with-sodium-glucose-cotransporter-2-inhibitors-a-disproportionality-analysis-in-the-who-global-pharmacovigilance-database-vigibase/369669.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study’s main objective regarding SGLT-2 inhibitors and cancer?","Question",{"text":113,"@type":114},"To conduct an exploratory, hypothesis-generating disproportionality analysis in the WHO pharmacovigilance database (Vigibase®) to identify signals of cancer risk associated with SGLT-2i use.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the analysis performed and what comparison drugs were used?",{"text":118,"@type":114},"Disproportionality analysis used Vigibase® reports from 2014 to 2023, comparing SGLT-2i use against GLP-1 analogues and DPP-4 inhibitors to assess reporting odds across cancer subtypes.",{"name":120,"@type":111,"acceptedAnswer":121},"Which cancer types showed increased reporting signals for SGLT-2 inhibitors?",{"text":122,"@type":114},"The study found increased reporting odds ratios for bladder cancer (ROR 4.46, 95% CI 3.23–6.17) and kidney cancer (ROR 1.84, 95% CI 1.25–2.69), while other cancer subtypes were not reported with similar increases.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369669,1790219133,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Drug Safety (2025) 48:933–941  \n[https://doi.org/10.1007/s40264-025-01546-5](https://doi.org/10.1007/s40264-025-01546-5)  \nInvestigating Risk of Cancer with Sodium‑Glucose Cotransporter  \n2 Inhibitors: A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase®  \nPaul Gautier1,2,3 · Meyer Elbaz3 · Frédéric Bouisset3 · Fabien Despas1,2 · François Montastruc1,2  \nAccepted: 18 March 2025 / Published online: 15 April 2025 © The Author(s) 2025  \nAbstract  \nIntroduction Use of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) has significantly increased due to their cardiovascular benefits. Whether SGLT-2is increase risk of cancer has been of concern since first clinical trials, but this question remains unclear because of methodological limitations in previous studies.  \nMethods We conducted a disproportionality analysis using Vigibase® between 2014 and 2023 to estimate the association between SGLT-2i use and the risk of reporting of different subtypes of cancers, compared with glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors.  \nResults Among 644 reported cases of cancer associated with SGLT-2i use, 427 (66.3%) were male, with a mean age of 66.5 ± 9.7 years. Sodium-glucose cotransporter 2 inhibitors showed increased reporting odds ratio for bladder cancer (ROR 4.46, 95% CI 3.23–6.17) and kidney cancer (ROR 1.84, 95% CI 1.25–2.69), but not for all other cancer subtypes.  \nConclusion In this disproportionality analysis with a hypothesis-generating approach, SGLT-2is are associated with an increased risk of reporting bladder and kidney cancer. There is a need of an urgent clarification of this signal with further long-term observational studies.  \n* François Montastruc  \nfrancois.montastruc@univ-tlse3.fr  \n1 Department of Medical and Clinical Pharmacology, Faculty of Medicine, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU), 37 Allées Jules Guesde, 31000 Toulouse, France  \n2 Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Centre d’Investigation Clinique 1436, Toulouse University Hospital, Toulouse, France  \n3 Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 31059 Toulouse, France  \nGraphical Abstract  \nGraphical abstract of the study design and results. CI confidence interval, DPP-4i dipeptidyl peptidase 4 inhibitors, GLP-1a glucagon-like peptide 1 agonists, ROR reporting odds ratio, SGLT-2is sodium-glucose cotransporter 2 inhibitors  \n1 Introduction  \nThe use of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) has widely increased in recent years because of a great improvement in cardiovascular outcomes [1, 2] . Since SLGT-2is are chronic therapy, we can expect long exposure among diabetic individuals. Some other antidiabetic drugs such as pioglitazone have shown an increased risk of bladder cancer, with a dose-and duration-dependent effect [3] .  \nSafety data regarding SGLT-2is and their association with cancer are currently contradictory and debated, particularly with bladder cancer [4] . This ongoing discussion has been of concern since the inception of research into these medications. Indeed, dapagliflozin triggered an alert and the US Food and Drug Administration (FDA) advisory committee first denied approval in 2011 [5] due toa disproportion of bladder cancer cases in clinical trials. This was later attributed to detection bias due to misdiagnosis of bladder cancer patients before their inclusion [6] . Furthermore, animal models did not show an increased risk of bladder cancer with dapagliflozin exposure up to 2 years [7] . At last, a population-based cohort study found no short-term increased risk of bladder cancer among over 450,000 new users of SGLT-2is compared to users of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) agonists [8] . However, this study has several limitations including the short follow-up duration (median follow-up ran","cbCaif1Zqokey1IW","https://ap.wps.com/l/cbCaif1Zqokey1IW","pdf",1416409,"English","# Abstract\n# Introduction\n# Methods","[{\"question\":\"What was the study’s main objective regarding SGLT-2 inhibitors and cancer?\",\"answer\":\"To conduct an exploratory, hypothesis-generating disproportionality analysis in the WHO pharmacovigilance database (Vigibase®) to identify signals of cancer risk associated with SGLT-2i use.\"},{\"question\":\"How was the analysis performed and what comparison drugs were used?\",\"answer\":\"Disproportionality analysis used Vigibase® reports from 2014 to 2023, comparing SGLT-2i use against GLP-1 analogues and DPP-4 inhibitors to assess reporting odds across cancer subtypes.\"},{\"question\":\"Which cancer types showed increased reporting signals for SGLT-2 inhibitors?\",\"answer\":\"The study found increased reporting odds ratios for bladder cancer (ROR 4.46, 95% CI 3.23–6.17) and kidney cancer (ROR 1.84, 95% CI 1.25–2.69), while other cancer subtypes were not reported with similar increases.\"}]","Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors - A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase® | PDF",1790184006,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d7395ca96f4c63a6912fdd3c11815a6.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2007466516b683d42154ef1a47bb075e.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaca7c7f08b64d06ac8d98d70bc86c86.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29ceb1e73edcec2518e9579c10dab34b.webp",980,1301]